Purdue Pharma L.P. v. State of Mississippi

CourtMississippi Supreme Court
DecidedOctober 18, 2018
Docket2017-IA-00300-SCT
StatusPublished

This text of Purdue Pharma L.P. v. State of Mississippi (Purdue Pharma L.P. v. State of Mississippi) is published on Counsel Stack Legal Research, covering Mississippi Supreme Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Purdue Pharma L.P. v. State of Mississippi, (Mich. 2018).

Opinion

IN THE SUPREME COURT OF MISSISSIPPI

NO. 2017-IA-00300-SCT

PURDUE PHARMA L.P., PURDUE PHARMA, INC., THE PURDUE FREDERICK COMPANY, INC., TEVA PHARMACEUTICALS, USA, INC., CEPHALON, INC., JOHNSON & JOHNSON, JANSSEN PHARMACEUTICALS, INC., ORTHO- McNEIL-JANSSEN PHARMACEUTICALS, INC. n/k/a JANSSEN PHARMACEUTICALS, INC., JANSSEN PHARMACEUTICA, INC., n/k/a JANSSEN PHARMACEUTICALS, INC., ENDO HEALTH SOLUTIONS INC., ENDO PHARMACEUTICALS, INC., WATSON LABORATORIES, INC. n/k/a ACTAVIS LABORATORIES UT, INC., ACTAVIS LLC AND ACTAVIS PHARMA, INC. f/k/a WATSON PHARMA, INC.

v.

STATE OF MISSISSIPPI

DATE OF JUDGMENT: 02/13/2017 TRIAL JUDGE: HON. DENISE OWENS TRIAL COURT ATTORNEYS: GEORGE W. NEVILLE JACQUELINE H. RAY JENNIFER F. CONNOLLY JOE N. TATUM JOHN LEE DAVIDSON STEPHEN L. THOMAS CHRISTOPHER A. SHAPLEY JOSEPH ANTHONY SCLAFANI STEVEN A. REED CHAD ROBERTS HUTCHINSON DAVID F. MARON JAMES WILLIAM MATTHEWS STEPHANIE M. RIPPEE STEVE W. BERMAN R. DAVID KAUFMAN BRIAN M. ERCOLE J. GORDON COONEY, JR. TINOS DIAMANTATOS ALAN W. PERRY SIMON TURNER BAILEY CAROLYN J. KUBOTA CHAD ROBERTS HUTCHINSON CHARLES C. LIFLAND IVANA CINGEL J. CARTER THOMPSON, JR. JOSHUA M. DAVIS SAMUEL DEUCALION GREGORY JASON LIRAN DRORI KATY ELLEN KOSKI PAUL STEPHENSON PATRICK J. FITZGERALD COURT FROM WHICH APPEALED: HINDS COUNTY CHANCERY COURT ATTORNEYS FOR APPELLANTS: JOSEPH ANTHONY SCLAFANI R. DAVID KAUFMAN CHRISTOPHER A. SHAPLEY SHEILA BIRNBAUM MARK S. CHEFFO HAYDEN A. COLEMAN STEPHEN L. THOMAS ALAN W. PERRY SIMON TURNER BAILEY JOSHUA M. DAVIS BRIAN M. ERCOLE J. GORDON COONEY, JR. TINOS DIAMANTATOS STEVEN A. REED CHAD ROBERTS HUTCHINSON CHRISTY D. JONES ADAM JULIUS SPICER CHARLES C. LIFLAND IVANA CINGAL CAROLYN J. KUBOTA

2 J. CARTER THOMPSON, JR. DAVID F. MARON SAMUEL DEUCALION GREGORY ATTORNEYS FOR APPELLEE: OFFICE OF THE ATTORNEY GENERAL BY: GEORGE W. NEVILLE JACQUELINE H. RAY GORDON GARLAND LYELL, III GEOFFREY C. MORGAN SAMUEL MARTIN MILLETTE JOHN LEE DAVIDSON JOE N. TATUM STEVE W. BERMAN JENNIFER F. CONNOLLY JAMES L. WARD, JR. ROBERT S. WOOD NATURE OF THE CASE: CIVIL - OTHER DISPOSITION: AFFIRMED AND REMANDED -10/18/2018 MOTION FOR REHEARING FILED: MANDATE ISSUED:

BEFORE KITCHENS, P.J., KING AND BEAM, JJ.

KING, JUSTICE, FOR THE COURT:

¶1. In this interlocutory appeal, the Court must determine whether the location of a

foreign corporation’s registered agent is relevant when determining the appropriate venue

for an action. We find that the adoption of the Registered Agents Act (“RAA”) made the

location of a corporation’s registered agent irrelevant for purposes of venue.

FACTS AND PROCEDURAL HISTORY

¶2. On December 15, 2015, the State of Mississippi filed a complaint in the Hinds County

Chancery Court against fifteen pharmaceutical manufacturers and their affiliates

(“Defendants”). According to the complaint, opioids originally were designed to treat “short-

3 term post-surgical and trauma-related pain, and for palliative (end-of-life) care.” However,

in an effort to increase profits, the State alleged that Defendants employed a wide variety of

deceptive and misleading practices designed to enter and conquer the chronic-pain market.

The State alleged that Defendants, despite knowledge of the addictive nature of opioids,

engaged in a marketing campaign “to create a profound transformation in medical and public

perception that would permit the use of opioids not only for acute and palliative care, but also

for long periods of time to treat more common aches and pains, like lower back pain,

arthritis, and headaches.”

¶3. As a result, opioids moved from a niche category of drugs to the most prescribed class

of drugs in America. The State averred that, in an opioid study, two-thirds of patients who

consumed opioids for more than ninety days still were taking opioids approximately five

years later.1 The State also alleged that in 2012, prescription opioid use contributed to 16,007

deaths nationally. Specific to Mississippi, in 2012, ninety percent of drug-overdose deaths

were caused by prescription drugs; most of the deaths were accidental. The complaint stated,

Defendants’ deceptive marketing campaign deprived Mississippi patients and their doctors of the ability to make informed medical decisions and, instead, caused important, sometimes life-or-death decisions to be made based not on science, but on hype. Defendants deprived patients, their doctors, and health care payers of the chance to exercise informed judgment and subjected them to enormous costs and suffering.

¶4. The State alleged four common-law claims (fraud, negligent misrepresentation, unjust

1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235603/ (last visited October 16, 2018).

4 enrichment, and public nuisance), and a claim pursuant to the Mississippi Consumer

Protection Act (“MCPA”), Mississippi Code Section 75-24-9. The complaint stated that the

Hinds County Chancery Court “has subject matter jurisdiction over this action pursuant to

MISS. CODE ANN. § 75-24-9, because the State brings this action, in part, to restrain by

permanent injunction the use of a method, act, or practice prohibited by MISS. CODE ANN.

§ 75-24-5.” In addition, the complaint stated that venue was proper pursuant to Mississippi

Code Sections 11-11-3, 11-5-1, 75-24-9, and 9-5-81; and Article 6, Section 159, of the

Mississippi Constitution.2

¶5. The parties do not dispute that each defendant’s principal place of business was

located outside the State of Mississippi. On March 3, 2016, Defendants filed a joint motion

to transfer for improper venue and to dismiss the complaint for failure to state a claim.

Defendants moved the trial court to transfer the action from the Hinds County Chancery

Court to the Rankin County Chancery Court pursuant to Mississippi Rules of Civil Procedure

12(b)(3) and 82(d).3 Attached to the motion was the affidavit of Stephanie M. Rippee,

2 The State’s complaint contains allegations of violations of Mississippi’s Medicaid Fraud Control Act, Mississippi Code Sections 43-13-201 to -607 (Rev. 2015). Pursuant to the Medicaid Fraud Control Act, actions “may be filed in the circuit court of the First Judicial District of Hinds County. . . .” Miss. Code Ann. § 43-13-223 (Rev. 2015). The State offered no argument about why the Mississippi Medicaid Fraud Control Act did not control venue. Unlike the MPCA, no consent is needed under the Medicaid Fraud Control Act for venue to be proper in Hinds County. 3 Mississippi Rule of Civil Procedure 82(d) provides,

When an action is filed laying venue in the wrong county, the action shall not be dismissed, but the court, on timely motion, shall transfer the action to the

5 attorney of record for Defendants. Although each of Defendants’ principal places of business

were located outside the State of Mississippi, Rippee stated that, according to the Mississippi

Secretary of State’s website, Actavis Pharma had appointed as its registered agent in

Mississippi CT Corporation System, which was located at 645 Lakeland East Drive, Suite

101, Flowood, Rankin County. In addition, Cephalon, Inc., had appointed as its registered

agent Corporate Creations Network, Inc., located at 232 Market Street, Flowood, Rankin

County.4

¶6. The State argued in opposition that the Mississippi Legislature passed the RAA to

eliminate the relevance of registered agents to the question of venue. The trial court agreed,

finding that the passage of the RAA made the location of a foreign corporation’s registered

Free access — add to your briefcase to read the full text and ask questions with AI

Related

ERA Franchise Systems, Inc. v. Mathis
931 So. 2d 1278 (Mississippi Supreme Court, 2006)
Park on Lakeland Drive, Inc. v. Spence
941 So. 2d 203 (Mississippi Supreme Court, 2006)
Penn Nat. Gaming, Inc. v. Ratliff
954 So. 2d 427 (Mississippi Supreme Court, 2007)
Holmes v. McMillan
21 So. 3d 614 (Mississippi Supreme Court, 2009)
Union National Life Ins. Co. v. Crosby
870 So. 2d 1175 (Mississippi Supreme Court, 2004)
Southern Leisure Homes, Inc. v. Hardin
742 So. 2d 1088 (Mississippi Supreme Court, 1999)
Pitalo v. GPCH-GP, INC.
933 So. 2d 927 (Mississippi Supreme Court, 2006)
Ross v. Ross
208 So. 2d 194 (Mississippi Supreme Court, 1968)
Crenshaw v. Roman
942 So. 2d 806 (Mississippi Supreme Court, 2006)
American Home Products Corp. v. Sumlin
942 So. 2d 766 (Mississippi Supreme Court, 2006)
Capital City Ins. v. GB" Boots" Smith
889 So. 2d 505 (Mississippi Supreme Court, 2004)
Guice v. Mississippi Life Ins. Co.
836 So. 2d 756 (Mississippi Supreme Court, 2003)
Price v. Price
32 So. 2d 124 (Mississippi Supreme Court, 1947)
Cleveland Smith v. Kansas City Southern Railway Company
214 So. 3d 272 (Mississippi Supreme Court, 2017)
Drake L. Lewis v. Tonia D. Lewis Pagel
233 So. 3d 740 (Mississippi Supreme Court, 2017)
City of Jackson, Mississippi v. Ben Allen
242 So. 3d 8 (Mississippi Supreme Court, 2018)
KD Hattiesburg 1128, Inc. v. Turtle Creek Crossing, LLC
237 So. 3d 157 (Mississippi Supreme Court, 2018)
State of Mississippi v. Walgreen Co.
250 So. 3d 465 (Mississippi Supreme Court, 2018)
Wilkerson v. Goss
113 So. 3d 544 (Mississippi Supreme Court, 2013)
Green v. Winona Elevator Company
319 So. 2d 224 (Mississippi Supreme Court, 1975)

Cite This Page — Counsel Stack

Bluebook (online)
Purdue Pharma L.P. v. State of Mississippi, Counsel Stack Legal Research, https://law.counselstack.com/opinion/purdue-pharma-lp-v-state-of-mississippi-miss-2018.